BioArctic Partner Eisai to Present Long-Term Lecanemab Data at AD/PD 2026
Event summary
- Eisai will present real-world efficacy and safety data on lecanemab at AD/PD 2026, including four-year data from the Clarity AD Open-Label Extension trial.
- BioArctic's co-founder Professor Lars Lannfelt will present on lecanemab's mechanisms of action and binding profile.
- BioArctic will also present a poster on exidavnemab in Parkinson's disease.
- Lecanemab is approved in 53 countries and under regulatory review in 6 others, with subcutaneous formulations under review in the US and China.
The big picture
BioArctic and Eisai's long-term collaboration on lecanemab underscores the strategic importance of anti-amyloid therapies in Alzheimer's disease treatment. The focus on real-world data and regulatory expansions reflects the industry's shift toward demonstrating long-term value and accessibility of novel therapies. With lecanemab approved in multiple markets and subcutaneous formulations under review, the partnership is positioning itself at the forefront of neurodegenerative disease treatment.
What we're watching
- Regulatory Progress
- Whether Eisai's subcutaneous lecanemab formulations gain approval in the US and China by mid-2026, expanding treatment options.
- Real-World Efficacy
- How the long-term real-world data on lecanemab's safety and effectiveness compares to clinical trial results.
- Pipeline Development
- The pace at which BioArctic advances exidavnemab through clinical trials for Parkinson's disease.
Related topics